Clinical Implications of Isolated Bone Failure Without Systemic Disease Progression During EGFR-TKI Treatment

IBF without systemic disease progression frequently occurs in patients with clinical benefits from EGFR-TKI and is associated with better survival. This finding requires future studies to explore the differential activity of EGFR-TKI in the bones over time or in preference to other organs.